Delivery Order SPE2DB20D2104-SPE2DB24FV76E

Award Date 8/16/24
Potential Completion Date 8/19/24
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of 1,000 capsules of Tamsulosin HCL 0.4 mg to the Defense Logistics Agency (DLA). The contract, valued at $4,053.22, was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $1,081.48 firm fixed-price delivery order is for the supply of 4,565,546,920 units of Tamsulosin Hydrochloride 0.4 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025, which enables the DLA to efficiently procure a comprehensive range of medical commodities from...
This federal contract award is for the delivery of 1,000 capsules of the prescription medication Tamsulosin Hydrochloride 0.4 mg. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The total ceiling value of the contract is $4,995.20, and it is structured as a firm fixed-price delivery order. The contract has an ultimate completion date of April 24, 2024. Amerisourcebergen holds a larger...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 1,000 units of the medication Tamsulosin Hydrochloride 0.4 mg capsule, with a ceiling value of $11,118.38. The contract is a firm fixed-price delivery order with a completion date of January 3, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999...
This federal contract award, valued at $1,912.77, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,565,683,725 units of Tamsulosin HCl 0.4 mg capsules. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is set for September 5, 2024. The contract was not set aside for a specific business type. This award is likely part of a larger Indefinite Delivery...
This federal contract award is for the delivery of 4,563,310,435 units of Tamsulosin HCL 0.4 mg capsules to the Defense Logistics Agency (DLA), which is a defense agency. The contract was awarded on January 11, 2024, to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for a ceiling value of $1,541.82. This is a delivery order contract with a firm fixed price, and the ultimate completion date is January 12, 2024. The contract does not have a set-aside designation, indicating open...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,566,352,432 units of Tamsulosin Hydrochloride 0.4 mg capsules. The contract has a ceiling value of $2,486.38 and a completion date of November 7, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,120.82, is for the delivery of 1,000 capsules of Tamsulosin HCL 0.4 mg. The contract is a Firm Fixed Price Delivery Order with a completion date of July 26, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides $1,604.24 for the delivery of 4,565,471 units of the prescription drug Tamsulosin Hydrochloride 0.4 mg Capsules. The contract, issued by the Defense Logistics Agency (DLA), is a Delivery Order type with a Firm Fixed Price pricing structure. The contract has an ultimate completion date of August 16, 2024. Amerisourcebergen, through its Corporate Office division, has been awarded this...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,699.60, is for the delivery of 1,000 units of the prescription medication Tamsulosin HCL 0.4 mg Capsule. The contract has an ultimate completion date of December 27, 2024 and was awarded on December 26, 2024. It is a firm fixed price delivery order contract with no set-aside designation,...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB24FV76E
    Delivery Order

This federal contract award is for the delivery of 100 capsules of the drug Tamsulosin Hydrochloride 0.4 mg to the Defense Logistics Agency (DLA). The contract has a ceiling value of $1,088.68 and was awarded to the prime contractor, Amerisourcebergen Drug Corp, on August 16, 2024, with a completion date of August 19, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 10:24 AM